Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
Sponsor: University of Pennsylvania
Summary
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C-M503. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with Parkinson's disease (PD). Investigators will compare uptake in participants with PD versus participants with multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), as well as non-Parkinsonism volunteers. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt) (non-clinical site) Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.
Official title: Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-M503
Key Details
Gender
All
Age Range
40 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2024-02-16
Completion Date
2029-02
Last Updated
2025-04-22
Healthy Volunteers
Yes
Conditions
Interventions
11C-M503 PET
2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-M503
Brain MRI
MRI scan of brain.
Amyloid PET
PET scan with Florbetaben F18 or 11C-PiB
Neurological assessments
Neurological assessments, including a video interview.
Locations (3)
Yale New Haven Hospital
New Haven, Connecticut, United States
Washington University in St. Louis
St Louis, Missouri, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States